Data / Form D filings / Tune Therapeutics, Inc.
Tune Therapeutics, Inc.: Form D filing
Tune Therapeutics, Inc., a biotechnology company in Seattle, WA, filed a Form D with the SEC in 2025. The latest, on January 24, 2025, reports $182.4 million sold of a $208 million offering to 39 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 1930 Boren Avenue, Floor 5, Seattle, WA, 98101
- Phone
- (855) 755-8863
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Year incorporated
- 2020
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 2053139
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Jan 24, 2025 | New notice | $208,045,929 | $182,414,405 | $25,631,524 | 39 | Mar 9, 2023 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Dan McHugh | Executive Officer, Director | |
| Akira Matsuno | Executive Officer | |
| Blythe Sather | Executive Officer | |
| Derek Jantz | Executive Officer | |
| Charles Gersbach | Director | |
| John McHutchison | Director | |
| Yuan Zhang | Executive Officer | |
| Zachary Hale | Executive Officer | |
| Ali Behbahani | Director |
Other biotechnology companies in Washington that filed recently
- Key Proteo, Inc. $2.3 million · Oct 23, 2026
- Inmedix, Inc. $4 million · Oct 22, 2026
- Q-Immune, Inc. $25,000 · Sep 28, 2026
- Hexamer Therapeutics, Inc $500,000 · Sep 15, 2026
- MalarVx, Inc. $125,000 · Aug 25, 2026
- Strella Biotechnology, Inc. $1.8 million · Aug 14, 2026
Every Form D from the week of Jan 20, 2025 · All recent filings in Washington · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Tune Therapeutics, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.